Security
Zivo Bioscience, Inc. Common Stock · ZIVO
ZIVOOTCCommon stockCurrentCIK 1101026Updated Oct 6, 2026
ZIVO price & chart
Loading TradingView…
OTC:ZIVO on TradingView ↗About the company
ZIVO Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q2 2023 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 559,452Source | 495,587Source | 2,102,037Source | 703,327Source | 575,588Source | 710,330Source | 1,331,334Source | 816,396Source | 1,643,122Source | 555,715Source | 2,123,019Source | 8,990,178Source |
| Property, Plant and Equipment, NetUSD | — | — | 0Source | — | — | 0Source | — | — | — | 0Source | 0Source | 0Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | — | — | — | — | — | — | — | 1,799,263Source | 8,901,875Source |
| Accounts Receivable | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | — | — |
| Assets, CurrentUSD | 281,399Source | 436,545Source | 1,947,869Source | 409,894Source | 495,127Source | 530,075Source | 1,022,923Source | 710,617Source | 1,635,442Source | 425,377Source | 1,901,679Source | 8,959,953Source |
| Prepaid Expense and Other Assets, CurrentUSD | 224,177Source | 249,348Source | 460,632Source | 365,707Source | 492,661Source | 509,008Source | 505,734Source | 568,241Source | 90,789Source | 147,262Source | 102,416Source | 58,078Source |
| Operating Lease, Right-of-Use AssetUSD | 270,373Source | 22,305Source | 122,110Source | 285,753Source | 48,403Source | 145,241Source | 300,731Source | 73,721Source | 0Source | 98,280Source | 189,282Source | 27,225Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 3,846,055Source | 2,578,656Source | 3,196,079Source | 3,244,073Source | 2,871,202Source | 3,855,162Source | 2,948,613Source | 3,085,295Source | 2,158,019Source | 2,761,558Source | 2,133,641Source | 2,947,969Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,832Source | 3,490Source | 1,742Source | 3,817Source | 3,319Source | 9,420Source | 3,791Source | 2,791Source | 3,621Source | 2,383Source | 9,420Source | 9,420Source |
| Additional Paid in CapitalUSD | 140,560,590Source | 133,278,605Source | 120,577,382Source | 140,273,406Source | 130,797,635Source | 116,693,992Source | 139,556,668Source | 122,588,510Source | 136,448,032Source | 121,373,488Source | 115,784,488Source | 114,259,830Source |
| Retained Earnings (Accumulated Deficit)USD | -143,851,025Source | -135,365,164Source | -121,673,166Source | -142,817,969Source | -133,096,568Source | -119,848,244Source | -141,177,738Source | -124,860,200Source | -136,966,550Source | -123,581,714Source | -115,804,530Source | -108,227,041Source |
| Stockholders' Equity Attributable to ParentUSD | -3,286,603Source | -2,083,069Source | -1,094,042Source | -2,540,746Source | -2,295,614Source | -3,144,832Source | -1,617,279Source | -2,268,899Source | -514,897Source | -2,205,843Source | -10,622Source | 6,042,209Source |
| Liabilities and EquityUSD | 559,452Source | 495,587Source | 2,102,037Source | 703,327Source | 575,588Source | 710,330Source | 1,331,334Source | 816,396Source | 1,643,122Source | 555,715Source | 2,123,019Source | 8,990,178Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 3,614,268Source | 2,578,656Source | 3,174,052Source | 2,959,588Source | 2,871,202Source | 3,804,242Source | 2,612,701Source | 3,085,295Source | 2,041,822Source | 2,761,558Source | 2,027,722Source | 2,947,969Source |
| Operating Lease, Liability, CurrentUSD | 65,713Source | 22,027Source | 110,398Source | 63,219Source | 50,920Source | 106,687Source | 60,793Source | 79,033Source | 0Source | 106,342Source | 99,259Source | 15,178Source |
| Accounts Payable, CurrentUSD | 992,990Source | 787,599Source | 643,812Source | 860,939Source | 1,093,469Source | 1,273,437Source | 655,279Source | 705,841Source | 547,090Source | 993,090Source | 490,670Source | 654,333Source |
| Operating Lease, Liability, NoncurrentUSD | 220,124Source | — | 22,027Source | 237,523Source | — | 50,920Source | 81,458Source | — | 116,197Source | 0Source | 105,919Source | 0Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,613,940Source | 1,130,274Source | 823,779Source | 1,433,953Source | 1,002,999Source | 681,910Source | 1,224,320Source | 1,287,920Source | 1,096,178Source | 1,148,770Source | 398,176Source | — |
cash flow · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -2,268,597Source | — | -8,236,368Source | — | -1,278,486Source | -13,384,836Source | 7,777,184Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | — | — | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | — | 1,511,086Source | 89,502Source | 297,653Source | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -2,211Source | 0Source | -1,524Source | 3,735Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 108,189Source | -287,249Source | -446,000Source | 502,420Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,430,238Source | -1,699,118Source | -4,313,510Source | -5,799,893Source | -7,102,612Source | -6,803,333Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 404,985Source | 1,563,379Source | 5,581,572Source | 4,275,010Source | 0Source | 15,567,346Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 57,222Source | 159,403Source | 9,823Source | 2,466Source | 517,189Source | 138,641Source | 1,542,442Source | 274,380Source | — | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 2,400Source | 2,056Source | 18,955Source | 72,178Source | 10,920Source | 3,084Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | 0Source | — |
| Additional Financial Items | ||||||||||||
| Accretion ExpenseUSD | — | — | — | — | — | — | — | — | 240,606Source | 254,637Source | — | — |
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 2,692,462Source | 3,377,512Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 122,520Source |
| General and Administrative ExpenseUSD | — | — | 836,187Source | 1,943,126Source | 1,171,137Source | 5,977,277Source | 1,439,552Source | 975,574Source | 10,275,914Source | 5,897,594Source | 6,491,704Source | 6,932,921Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,033,056Source | -2,268,597Source | -1,640,232Source | -8,236,368Source | -4,211,188Source | -1,278,486Source | -13,384,836Source | -7,777,184Source | -8,745,293Source | -9,163,366Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | -13,319Source | -110,761Source |
| Operating ExpensesUSD | — | — | 1,039,631Source | 2,269,487Source | 1,650,794Source | 8,229,602Source | 4,208,788Source | 1,288,341Source | 13,410,849Source | 7,274,622Source | 8,731,974Source | 9,052,605Source |
| Operating Lease, ExpenseUSD | — | — | 23,515Source | 27,236Source | 23,515Source | 27,235Source | 23,515Source | 27,236Source | 104,346Source | 108,942Source | 102,249Source | 25,879Source |
| Proceeds from Issuance of Common StockUSD | — | — | 245,000Source | 1,414,474Source | 150,000Source | — | — | 130,782Source | 5,602,269Source | 485,000Source | 0Source | 1,514,970Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 32,775Source |
| Repayments of Long-term Debt | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Income Tax Expense (Benefit) | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Other Nonoperating Income (Expense) | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2024 | Q4 2023 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 65,625Source | 31,500Source | 53,400Source | 0Source | 0Source | 35,720Source | 157,220Source | 27,650Source | 0Source | 0Source |
| Cost of RevenueUSD | — | — | 44,337Source | 22,050Source | 35,478Source | 0Source | 0Source | 23,218Source | 108,268Source | 16,040Source | — | — |
| Operating Income (Loss)USD | — | — | -1,018,343Source | -2,260,037Source | -1,632,872Source | -8,229,602Source | -4,208,788Source | -1,275,839Source | -13,361,897Source | -7,263,012Source | -8,731,974Source | -9,052,605Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,033,056Source | -2,268,597Source | -1,640,232Source | -8,236,368Source | -4,211,188Source | -1,278,486Source | -13,384,836Source | -7,777,184Source | -8,745,293Source | -9,163,366Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.27Source | -0.67Source | -0.43Source | -2.78Source | -1.12Source | -0.47Source | -4.23Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 3,817,172Source | 3,410,444Source | 3,810,065Source | 2,961,606Source | 3,750,079Source | 2,748,294Source | 3,167,153Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 836,187Source | 1,943,126Source | 1,171,137Source | 5,977,277Source | 1,439,552Source | 975,574Source | 10,275,914Source | 5,897,594Source | 6,491,704Source | 6,932,921Source |
| Gross ProfitUSD | — | — | 21,288Source | 9,450Source | 17,922Source | 0Source | 0Source | 12,502Source | 48,952Source | 11,610Source | — | — |
| Interest ExpenseUSD | — | — | 12,959Source | 8,560Source | 7,360Source | 6,766Source | 2,400Source | 2,647Source | — | 23,793Source | 13,319Source | 44,677Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | -13,319Source | -110,761Source |
| Operating ExpensesUSD | — | — | 1,039,631Source | 2,269,487Source | 1,650,794Source | 8,229,602Source | 4,208,788Source | 1,288,341Source | 13,410,849Source | 7,274,622Source | 8,731,974Source | 9,052,605Source |
| Operating Lease, ExpenseUSD | — | — | 23,515Source | 27,236Source | 23,515Source | 27,235Source | 23,515Source | 27,236Source | 104,346Source | 108,942Source | 102,249Source | 25,879Source |
| Other ExpensesUSD | — | — | 1,754Source | 0Source | 7,360Source | 6,766Source | 2,400Source | 2,647Source | 22,939Source | 514,172Source | — | — |
| Research and Development ExpenseUSD | — | — | 203,444Source | 326,361Source | 479,657Source | 2,252,325Source | 2,769,236Source | 312,767Source | 3,134,935Source | 1,377,028Source | 2,240,270Source | 2,119,684Source |
| Other Nonoperating Income (Expense) | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
| Income Tax Expense (Benefit) | — | — | — | — | — | — | — | —Source | — | — | — | — |
Offerings
Registration 333-273493
Filing attachments
zivo_ex991.htm · 8-K · 2026-03-30
EX-99.1 2 zivo_ex991.htm PRESS RELEASE zivo_ex991.htm EXHIBIT 99.1 ZIVO BIOSCIENCE, INC. ANNOUNCES INTENTION TO FILE FORM 15 TO VOLUNTARILY DEREGISTER AND SUSPEND ITS SEC REPORTING OBLIGATIONS TROY, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, today announced that its Board of Directors has determined to voluntarily delist its common…
Read attachment ↗zivo_ex992.htm · 8-K · 2026-03-30
EX-99.2 3 zivo_ex992.htm CEO LETTER TO SHAREHOLDERS zivo_ex992.htm EXHIBIT 99.2 ZIVO BIOSCIENCE, INC. Special Shareholder Letter From the Office of the CEO - John B. Payne Troy, Michigan March 27, 2026 Dear Fellow Shareholders, I am writing to inform you of a significant and carefully considered decision by the Board of Directors of ZIVO Bioscience, Inc. (“ZIVO” or the “Company”): we intend to deregister the Company’s securities with the Securities and Exchange Commission and cease p…
Read attachment ↗zivo_ex991.htm · 8-K · 2025-09-10
EX-99.1 2 zivo_ex991.htm PRESS RELEASE zivo_ex991.htm EXHIBIT 99.1 ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses TROY, Mich. (September 10, 2025) -- ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, today issued the following letter to shareholders from Chairman, President and Chief Executive…
Read attachment ↗zivo_ex41.htm · 8-K · 2025-07-14
EX-4.1 2 zivo_ex41.htm COMMON STOCK PURCHASE WARRANT zivo_ex41.htm EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE S…
Read attachment ↗